Collaborative Arrangements (Tables)

3 Months Ended

Mar. 31, 2020

Summarized financial information related to this collaboration is as follows:



	Three Months Ended March 31,
($ in millions)	2020		2019
Alliance revenue	$	145	$	79

Cost of sales⁽¹⁾	28		19
Selling, general and administrative	33		27
Research and development	36		45

($ in millions)	March 31, 2020		December 31, 2019
Receivables from AstraZeneca included in Other current assets	$	142	$	128
Payables to AstraZeneca included in Accrued and other current liabilities⁽²⁾	326		577

⁽¹⁾Represents amortization of capitalized milestone payments.

⁽²⁾Includes accrued milestone payments.

Summarized financial information related to this collaboration is as follows:



	Three Months Ended March 31,
($ in millions)	2020		2019
Alliance revenue	$	128	$	74

Cost of sales⁽¹⁾	35		51
Selling, general and administrative	11		19
Research and development	64		47

($ in millions)	March 31, 2020		December 31, 2019
Receivables from Eisai included in Other current assets	$	140	$	150
Payables to Eisai included in Accrued and other current liabilities ⁽²⁾	425		700
Payables to Eisai included in Other Noncurrent Liabilities ⁽³⁾	300		525

⁽¹⁾Represents amortization of capitalized milestone payments.

⁽²⁾Includes accrued milestone and future option payments.

⁽³⁾Includes accrued milestone payments.

Summarized financial information related to this collaboration is as follows:



	Three Months Ended March 31,
($ in millions)	2020		2019
Net sales of Adempas recorded by Merck	$	56	$	48
Alliance revenue	53		42
Total sales	109		90

Cost of sales⁽¹⁾	28		29
Selling, general and administrative	15		8
Research and development	25		30

($ in millions)	March 31, 2020		December 31, 2019
Receivables from Bayer included in Other current assets	$	50	$	49
Payables to Bayer included in Other Noncurrent Liabilities ⁽²⁾	375		375

⁽¹⁾Includes amortization of intangible assets.

⁽²⁾Represents accrued milestone payment.